Biosimilar infliximab use in paediatric IBD

Lisa Richmond, Lee Curtis, Victoria Garrick, Pam Rogers, Michelle Wilson, Rachel L Taylor, Paul Henderson, Richard Hansen, David Wilson, Richard Russell

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Biosimilar infliximab became available in the United Kingdom in 2015.
Paediatric experience to date on its use is limited. We prospectively evaluated the safety and efficacy of biosimilar infliximab (Remsima™) in two paediatric gastroenterology networks in patients with inflammatory bowel disease.
Original languageEnglish
JournalArchives of Disease in Childhood
Early online date7 Oct 2017
DOIs
Publication statusE-pub ahead of print - 7 Oct 2017

Fingerprint Dive into the research topics of 'Biosimilar infliximab use in paediatric IBD'. Together they form a unique fingerprint.

Cite this